QPPV.COM KNOWLEDGE ASSESSMENT

Knowledge Assessment: Defining Risk Minimisation Objectives and Implementation Pathways

Test your understanding of the concepts covered by GVP Module XVI: Defining Risk Minimisation Objectives and Implementation Pathways.

Question 1 of 10Pass mark: 80%

Question 1 of 10 Which statement best reflects appropriate QPPV oversight of risk minimisation?

The QPPV must personally conduct every distribution, training and implementation activity The QPPV should have visibility of significant decisions, responsibilities, proportionality and effectiveness, while operational tasks may be delegated The QPPV is responsible only for adverse event case processing The QPPV should approve every communication regardless of its significance

Question 2 of 10 When may a controlled-access or distribution system be particularly appropriate?

When safe use requires verification of a defined condition before supply or administration Whenever routine product information is legally required When the organisation wants to demonstrate a high level of procedural activity When the critical safety behaviour occurs after the medicine has been discontinued

Question 3 of 10 Why should risk minimisation be managed as a lifecycle rather than as a one-time activity?

Because all measures must be replaced annually Because new evidence, implementation experience and changes in clinical practice may require continuation, adaptation or replacement Because effectiveness evaluation is required only before implementation Because the original objective should remain unchanged regardless of new evidence

Question 4 of 10 What is the relationship between a critical behaviour and a desired clinical outcome?

They are always identical and should be measured with the same data A behaviour may be an intermediate step, while the desired outcome may be a clinical result such as reduced harm Clinical outcomes are relevant only for routine risk minimisation A successful behaviour change always proves that the clinical risk has been reduced

Question 5 of 10 Which unintended consequence should be considered when assessing a highly restrictive risk minimisation measure?

Only whether the intended adverse reaction decreased Potential delayed treatment, inappropriate substitution or unnecessary avoidance of beneficial therapy Whether the measure generated sufficient documentation Whether all patients received identical technical information

Question 6 of 10 What should national implementation of an EU-level risk minimisation requirement generally achieve?

Identical administrative procedures in every Member State regardless of healthcare structure Consistency in the underlying safety message and intended behaviour while allowing justified procedural adaptation Replacement of the scientific objective by national commercial preferences Removal of MAH oversight once a national process is established

Question 7 of 10 What is the purpose of a predefined effectiveness threshold?

To create a meaningful, scientifically defensible basis for judging whether the objective was achieved To ensure that every measure is judged successful after implementation To replace the need to define the risk minimisation objective To allow the threshold to be changed after results are known

Question 8 of 10 Which feature is most important for a checklist used as a risk minimisation measure?

It should be as comprehensive and lengthy as possible It should be used at the relevant workflow point and contain steps linked to genuine safety-critical decisions It should be available online even if users do not access it during the decision It should replace all professional judgement

Question 9 of 10 A medication error occurs during pharmacy dispensing, but the proposed intervention is a patient leaflet supplied after dispensing. What is the primary design concern?

The intervention may not reach the actor controlling the critical step Patient-facing measures are never appropriate Dispensing errors can only be addressed through a contraindication The measure should be evaluated only by the number of leaflets printed

Question 10 of 10 Why can evaluating a measure for a rare but serious risk require emphasis on intermediate evidence?

Rare risks do not require effectiveness evaluation Clinical events may be too infrequent for simple outcome comparisons, making implementation and behavioural evidence informative while surveillance continues Intermediate evidence is always stronger than clinical outcome evidence Rare risks should be evaluated only through material distribution

Knowledge Assessment: Defining Risk Minimisation Objectives and Implementation Pathways

Cookie Settings